Bolodeoku J, Gbaa T, Morris K, Whitehead S. Medicine Optimisation Using PCSK9 Monoclonal Antibodies (alirocumab and evolocumab) Concerning the European Atherosclerosis Society (EAS) of < 1.8 mmol/l LDL Cholesterol Target in a Secondary Care Lipid Clinic. BJHMR [Internet]. 2023Dec.17 [cited 2024Nov.22];10(6):91-102. Available from: https://journals.scholarpublishing.org/index.php/JBEMi/article/view/15955